|Other Names||Plasminogen activator inhibitor 2, PAI-2, Monocyte Arg-serpin, Placental plasminogen activator inhibitor, Serpin B2, Urokinase inhibitor, SERPINB2, PAI2, PLANH2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6562c was selected from the Center region of human PAI2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell- derived PAI-1.|
|Cellular Location||Cytoplasm. Secreted, extracellular space.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PAI2 inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.
Di Bernardo,M.C., Lung Cancer 65 (2), 237-241 (2009)Almeida-Vega,S., Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2), G414-G423 (2009)
If you have any additional inquiries please email technical services at email@example.com.